AbbVie Completes Acquisition of Pharmacyclics

Morgan Stanley Resumes Abbvie (ABBV) at Equalweight

Morgan Stanley resumed coverage on Abbvie (NYSE: ABBV) with an Equalweight rating.

For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.

Shares of Abbvie closed at $67.38 yesterday.

Cowen Raises Price Target on AbbVie (ABBV) Due to Enhanced Visability

Cowen maintains an Outperform rating on Abbvie (NYSE: ABBV), and raised the price target to $72.00 (from $70.00) to show for enhanced viability. Analyst Steve Scala says that ABBV has consistently delivered EPS upside, and it is possible that forecasts move up over time.... More

AbbVie (ABBV) Enters $5B Accelerated Common Stock Buyback Agreement

AbbVie (NYSE: ABBV) disclosed the following on Wednesday:

On May 26, 2015, AbbVie Inc. (AbbVie) entered into an accelerated share repurchase agreement (the agreement) with Morgan Stanley & Co. LLC (Morgan Stanley) to repurchase $5.0 billion (the prepayment amount) of AbbVies common stock. Morgan Stanley is expected to make an initial delivery of approximately 68 million shares of... More

AbbVie (ABBV) Announces Completion of Pharmacyclics Acquisition

AbbVie (NYSE: ABBV) has completed the acquisition of Pharmacyclics, Inc. (Nasdaq: PCYC) enhancing AbbVie's scientific and commercial presence in oncology. Pharmacyclics is a leader in the hematological oncology market with Imbruvica® (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological cancers, a $24 billion global market.

"The companies' shared expertise, combined with AbbVie's broad late-stage oncology pipeline, has the potential to transform the cancer treatment landscape for hematological malignancies and improve patient outcomes and quality of life," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.... More